Re­gen­eron’s $500M fund spot­lights cor­po­rate ven­ture’s in­flu­en­tial role in biotech

When Re­gen­eron an­nounced a $500 mil­lion cor­po­rate ven­ture cap­i­tal fund last week, it was the first time in years that a sto­ried large phar­ma had …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.